Seattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancer

Michael Jensen, left, and Steven Brugger are leading BrainChild Bio. (Photos via BrainChild Bio) Seattle biotech startup BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for one of the deadliest forms of childhood brain cancer. The Series A financing will primarily fund a pivotal Phase 2 clinical trial of an investigational therapy being developed for diffuse intrinsic pontine glioma, or DIPG.